Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
TNGX Stock Chart & Stats
$8.17
-$0.22(-6.34%)
At close: 4:00 PM EST
$8.17
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$1.03 - $9.70
Previous CloseN/A
Volume187.94K
Average Volume (3M)3.69M
Market Cap
$1.10B
Enterprise Value$813.64M
Total Cash (Recent Filing)$152.81M
Total Debt (Recent Filing)$34.76M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 30, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding134,594,000
10 Day Avg. Volume2,972,972
30 Day Avg. Volume3,694,941
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)1.69
Price to Sales (P/S)8.02
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue12.24
Enterprise Value/Gross Profit12.46
Enterprise Value/Ebitda-7.83
Forecast
1Y Price Target
$12.80Price Target Upside56.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$59.49M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTNG260 demonstrated a mPFS of 27 weeks in a pre-specified subgroup of checkpoint inhibitor-resistant STK11 mut/KRAS WT lung cancer patients, which is more than double the mPFS with standard-of-care.
Financial StabilityTango ended 3Q25 with $364.8M in pro forma cash, cash equivalents, and marketable securities, providing an operational runway into 2028.
Market InterestTNGX stock has risen 92% while the XBI was up 5%, indicating strong investor interest.
Bears Say
Clinical RisksRisks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates into registrational trials.
Competitive RisksCompetitive risks exist, especially with respect to other clinical-stage PRMT5 inhibitors.
Regulatory ChallengesThere is a risk of failure to achieve favorable clinical results with other candidates, specifically TNG456, and the inability to obtain regulatory approvals in a timely manner.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $1.03 and its highest was $9.70 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $1.10B.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Mar 30, 2026 which is in 134 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.051 by $0.191.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 134,594,000 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.051. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.80 (56.67% Upside)
$12.80 (56.67% Upside)
Blogger Sentiment
Bullish
TNGX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 12.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.41%
12-Months-Change
Fundamentals
Return on Equity
-51.65%
Trailing 12-Months
Asset Growth
-40.37%
Trailing 12-Months
Company Description
Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$12.80
▲(56.67% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
33.53% Insiders
8.37% Mutual Funds
0.22% Other Institutional Investors
47.46% Public Companies and
Individual Investors